160 related articles for article (PubMed ID: 3907279)
1. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
[TBL] [Abstract][Full Text] [Related]
2. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
[TBL] [Abstract][Full Text] [Related]
3. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
[TBL] [Abstract][Full Text] [Related]
4. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
[TBL] [Abstract][Full Text] [Related]
5. Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients.
Gerken A; Wetzel H; Benkert O
Pharmacopsychiatry; 1991 Jul; 24(4):132-7. PubMed ID: 1754609
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
Rothschild AJ; Samson JA; Bessette MP; Carter-Campbell JT
J Clin Psychiatry; 1993 Sep; 54(9):338-42. PubMed ID: 8104930
[TBL] [Abstract][Full Text] [Related]
7. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
8. Perphenazine decanoate in sesame oil vs. perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications.
Knudsen P; Hansen LB; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():11-4. PubMed ID: 3865500
[TBL] [Abstract][Full Text] [Related]
9. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
10. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
11. [Double-blind comparison of 2 depot neuroleptics (perphenazine enanthate and flupentixol decanoate) in chronic schizophrenia (author's transl)].
Eufe R; Wegener G
Nervenarzt; 1979 Aug; 50(8):534-9. PubMed ID: 394015
[No Abstract] [Full Text] [Related]
12. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.
Tang WK; Ungvari GS
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):373-9. PubMed ID: 12691772
[TBL] [Abstract][Full Text] [Related]
13. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.
Kistrup K; Gerlach J; Aaes-Jørgensen T; Larsen NE
Psychopharmacology (Berl); 1991; 105(1):42-8. PubMed ID: 1745710
[TBL] [Abstract][Full Text] [Related]
14. Depot neuroleptics: side effects and safety.
Marder SR
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
[TBL] [Abstract][Full Text] [Related]
15. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients.
Dencker SJ; Giös I; Mårtensson E; Nordén T; Nyberg G; Persson R; Roman G; Stockman O; Svärd KO
Psychopharmacology (Berl); 1994 Feb; 114(1):24-30. PubMed ID: 7846204
[TBL] [Abstract][Full Text] [Related]
16. [Therapy control of perphenazine. 2. Clinical aspects].
Kjeldsen CS; Larsen NE; Kragh-Sørensen P; Andersen E; Brøsen K; Gerholt F; Glue P; Hørder M; Klitgaard NA; Krarup G
Ugeskr Laeger; 1991 Aug; 153(34):2339-43. PubMed ID: 1897043
[TBL] [Abstract][Full Text] [Related]
17. [Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms].
Lejoyeux M; Gorwood P; Stalla-Bourdillon A; Adès J
Encephale; 1993; 19(1):17-21. PubMed ID: 8275889
[TBL] [Abstract][Full Text] [Related]
18. [Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].
György B; Robert K; László C; Andrea J;
Neuropsychopharmacol Hung; 2008 Dec; 10(5):293-303. PubMed ID: 19419015
[TBL] [Abstract][Full Text] [Related]
19. [Long-term clinical experience with clozapine].
Gelly F; Chambon O; Marie-Cardine M
Encephale; 1997; 23(5):385-96. PubMed ID: 9453932
[TBL] [Abstract][Full Text] [Related]
20. Reducing the dose of depot neuroleptics in stable schizophrenia.
Dale R; Longdon M; Seeman MV
J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
